Dynamics of the COVID -19 Related Publications

Sarkar, Biplab; Munshi, Anusheel; Ghosh, Bratin; Ganesh, T; Manikandan, A.; Biswal, Subhra Singhdha; Sahid, Tanweer; Rajagopalan, Bharath; Snegupta, Sinjini; Raychaudhuri, Sandipan; Bhattacharya, Jayanta; Gazi, Mahasin; De, A.; George, Kirubha; Ghosh, Tanmay; Akhtar, Jawed; Mondal, Sourav; Mukherjee, Mukti; Gupta, Rosalima; Roy, Subhasis; Jassal, Kanan; Rastogi, Khushboo; Bansal, Kanika; Chatterjee, Pallab; Biswas, Litan Naha; Bondopadhay, Shymasish; Pradhan, Anirudh; Mohanti, Bidhu Kalyan

doi:10.1101/2020.08.05.237313

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 related publications have reached a magnitude of 23000, 5898, and 5393 publications in PubMed, Elsevier, and RG (research gate), respectively, over a few months. 95 Review articles have highlighted the importance of hand-hygiene, travel restrictions, mask use, and physical distancing continuously. Rapid diagnostic assays, effective therapeutic strategies, and prevention through the rapid development of vaccines are the most important step in our battle against this virus.…”

Section: New Learning Points From This Reviewmentioning

confidence: 99%

Journey so far with COVID 19 – a comprehensive review

Roy¹

2021

Eur J Clin Exp Med

View full text Add to dashboard Cite

Introduction. The occurrence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged as a global pandemic with huge death tolls. Coronavirus disease 2019 (COVID-19) may progress from minimal infection to serious respiratory failure mandating treatment for a continuum of developed disease condition. Aim. The purpose of this review is to summarize the findings related to epidemiology, clinical manifestations, modes of transmission, diagnosis and the treatment modalities (both experimental and repurposed) for COVID-19. Material and methods. Literature were searched using various search engines like PubMed, SCOPUS, EMBASE, J-Gate, Google Scholar to look for review articles, randomized controlled trial results, prospective studies and, retrospective studies done on COVID-19 for the purpose of this comprehensive review. Analysis of the literature. The transmission seems to be occurring through droplet, fomite and aerosols (rarely). Currently there is no specific/targeted vaccine available. Priority is highly placed to identify possible treatment approaches to circumvention this disease. Conclusion. Till we find a vaccine, we have to strategize to optimally use the existing evidence of the indirect effects of these various available drugs for therapy and maintain a strict protocol for prevention and we must use triage system to admit only those critically ill or having severe disease.

show abstract

Section: New Learning Points From This Reviewmentioning

confidence: 99%

Journey so far with COVID 19 – a comprehensive review

Roy¹

2021

Eur J Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…The changes caused by the spread of Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) have a significant impact on cancer care (1), including radiation oncology practice (2)(3)(4). The new challenges were reflected by the increasing number of publications, which are helping the members of the professional community to share their experience and learn from each other (5).…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy for Lung Cancer During the COVID Pandemic – A Narrative Review of Practical Recommendations

Chatterjee

Bhattacharya

Ghosh

et al. 2021

JMRO

Self Cite

View full text Add to dashboard Cite

"Background: The coronavirus disease pandemic produced changes in the treatment approach of lung cancer patients. They represent a vulnerable population due to the negative impact of delays in diagnosis and treatment and also because of the impaired immune system. Radiation Therapy plays a crucial role in both curative and palliative settings, so finding the best approach for these patients in this context was attempted by many professionals. The aim of this study was to make a synthesis of the current published literature on this topic and summarize the recommendations. Material and methods: We searched the PubMed database for articles published between 20th December 2019 and 30th August 2020. We used 14 key words related to COVID 19 and Lung Cancer. The articles were selected by two senior clinicians who excluded overlapping information and prioritized original research reports and professional organization’s official recommendations. Results: There were 562 papers corresponding to the search criteria, of which 64 were analyzed. Treatment decision must be tailored according to the status of SARS CoV-2 positivity, the aim of the treatment (curative VS palliative), pathological type and clinical stage, disease complications, symptoms, prognostic, performance status, and alternative treatments. Hypofractionation is preferred whenever possible in order to minimize risk for patients and staff. Safety measures have to be implemented, with extra cautions if SARS CoV-2 positive patients have to be treated. Cone beam CT can be used early identification of lung infiltrates and special attention is recommended to differentiate Radiation pneumonitis from COVID-19 pneumonia. Journal of Medical and Radiation Oncology Journal homepage: www.jmedradonc.org Review 94 Conclusion: For SARS CoV-2 positive lung cancer patients the treatment should be postponed, until they are tested negative. For patients which are SARS CoV-2 negative treated with curative intent, hypofractionated schedules are preferred. Palliative treatments should be given according to the life threatening risk."

show abstract

Hypofractionated Postoperative Radiation Therapy for Breast Cancer – Do We Need More Evidence or Adapted Reimbursement Policies?

Chirila¹,

Ratoša

Marta

et al. 2021

JMRO

View full text Add to dashboard Cite

"More than 10 years ago, two pivotal trials, the Ontario Clinical Oncology Group trial and START B trial, firmly established that hypofractionated radiation therapy (RT) of 40–42.5 Gy in 15–16 fractions over 3 weeks after breast conserving surgery or mastectomy results in similar rates of local recurrence and normal tissue effects. This led to a new standard for postoperative whole breast and chest wall RT. Further trials confirmed these findings and show that hypofractionated RT can also be applied for other indications, including regional nodal RT and for ductal carcinoma in situ (DCIS). More recently, a so-called ultra-fractionation trial demonstrated that 26 Gy in 5 fractions over 1 week was non-inferior to 40 Gy, in 15 fractions in 3 weeks for local recurrence at 6 years and that late effects were similar between fractionation schedules being a treatment option for most patients with early breast cancer. Several countries and departments are now adopting hypofractionated schedules as a new standard for breast, chest wall or partial breast RT. In addition to the improvement in convenience and reduction in resources required, hypofractionated RT offers important benefits with respect to acute and late toxicity that can improve the quality of life of patients receiving breast RT."

show abstract

Dynamics of the COVID -19 Related Publications

Cited by 3 publications

References 7 publications

Journey so far with COVID 19 – a comprehensive review

Journey so far with COVID 19 – a comprehensive review

Radiotherapy for Lung Cancer During the COVID Pandemic – A Narrative Review of Practical Recommendations

Hypofractionated Postoperative Radiation Therapy for Breast Cancer – Do We Need More Evidence or Adapted Reimbursement Policies?

Contact Info

Product

Resources

About